These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34825292)

  • 21. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
    Prinzing BL; Gottschalk SM; Krenciute G
    Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
    Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
    J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR T Cells.
    Tudor T; Binder ZA; O'Rourke DM
    Neurosurg Clin N Am; 2021 Apr; 32(2):249-263. PubMed ID: 33781506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Salinas RD; Durgin JS; O'Rourke DM
    CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP; Li M; Li TF; Han SY
    Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
    Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
    Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
    Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
    Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity.
    Song EZ; Wang X; Philipson BI; Zhang Q; Thokala R; Zhang L; Assenmacher CA; Binder ZA; Ming GL; O'Rourke DM; Song H; Milone MC
    Mol Ther Oncolytics; 2022 Dec; 27():288-304. PubMed ID: 36458202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of the alpha
    Cobb DA; de Rossi J; Liu L; An E; Lee DW
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma.
    Liang T; Song Y; Gu L; Wang Y; Ma W
    Int J Gen Med; 2023; 16():4121-4141. PubMed ID: 37720174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions.
    Goutnik M; Iakovidis A; Still MEH; Moor RSF; Melnick K; Yan S; Abbas M; Huang J; Ghiaseddin AP
    Neurooncol Adv; 2024; 6(1):vdae025. PubMed ID: 38486856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
    Martínez Bedoya D; Dutoit V; Migliorini D
    Front Immunol; 2021; 12():640082. PubMed ID: 33746981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression.
    Luksik AS; Yazigi E; Shah P; Jackson CM
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells.
    Sengupta S; Katz SC; Sengupta S; Sampath P
    Cancer Lett; 2018 Oct; 433():131-139. PubMed ID: 29959057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updates On Chimeric Antigen Receptor-Mediated Glioblastoma Immunotherapy.
    Mao G; Sampath P; Sengupta S
    R I Med J (2013); 2017 Jun; 100(6):39-42. PubMed ID: 28564668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene Targets of CAR-T Cell Therapy for Glioblastoma.
    Wang C; Li Y; Gu L; Chen R; Zhu H; Zhang X; Zhang Y; Feng S; Qiu S; Jian Z; Xiong X
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.